Document Detail

Tricuspid valve replacement and levosimendan.
MedLine Citation:
PMID:  19002757     Owner:  NLM     Status:  MEDLINE    
Isolated tricuspid valve replacement, which is not a common operation, is associated with poor short and long-term results, and the postoperative morbidity and mortality rates are high. The main reason for these adverse effects is the acute manifestation of chronic right heart failure. To treat right heart failure, we used levosimendan for its inotropic and vasodilatatory effects, and it does not increase the calcium overload in myocardial cells. We report two cases of tricuspid valve replacement operations performed using levosimendan. Both patients receiving levosimendan tolerated the operations well, and their postoperative courses were uneventful.
Ferit Cicekcioglu; Ali Ihsan Parlar; Levent Altinay; Kerem Yay; Salih Fehmi Katircioglu
Related Documents :
23094737 - Coronary ct angiography for acute chest pain.
1790027 - Surgical management of pulmonary atresia with intact ventricular septum. right ventricu...
24859377 - Myoglobin functions in the heart.
15054517 - Congenital anomalies of the coronary circulation.
24703457 - Pathophysiology and potential treatments of pulmonary hypertension due to systolic left...
18489867 - Degenerative mitral valve regurgitation: surgical echocardiography.
Publication Detail:
Type:  Case Reports; Journal Article     Date:  2008-11-12
Journal Detail:
Title:  General thoracic and cardiovascular surgery     Volume:  56     ISSN:  1863-6705     ISO Abbreviation:  -     Publication Date:  2008 Nov 
Date Detail:
Created Date:  2008-11-12     Completed Date:  2009-01-16     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  101303952     Medline TA:  Gen Thorac Cardiovasc Surg     Country:  Japan    
Other Details:
Languages:  eng     Pagination:  559-62     Citation Subset:  IM    
Cardiovascular Surgery Clinic, Turkiye Yuksek Ihtisas Hospital, Ankara, Turkey.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Cardiopulmonary Bypass
Cardiotonic Agents / administration & dosage,  therapeutic use*
Follow-Up Studies
Heart Failure / drug therapy*
Heart Rate
Heart Valve Prosthesis*
Heart Valve Prosthesis Implantation*
Hydrazones / administration & dosage,  therapeutic use*
Pyridazines / administration & dosage,  therapeutic use*
Time Factors
Treatment Outcome
Tricuspid Valve* / surgery
Vasodilator Agents / administration & dosage,  therapeutic use*
Reg. No./Substance:
0/Cardiotonic Agents; 0/Hydrazones; 0/Pyridazines; 0/Vasodilator Agents; 131741-08-7/simendan

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Thyroid carcinoma with extensive tumor thrombus in the atrium.
Next Document:  Levosimendan and severe pulmonary hypertension during open heart surgery.